[go: up one dir, main page]

ZA200106725B - Use of an enterobacterium protein ompa associated with an antigen for generating an antiviral antiparasitic or antitumoral cytotoxic response. - Google Patents

Use of an enterobacterium protein ompa associated with an antigen for generating an antiviral antiparasitic or antitumoral cytotoxic response.

Info

Publication number
ZA200106725B
ZA200106725B ZA200106725A ZA200106725A ZA200106725B ZA 200106725 B ZA200106725 B ZA 200106725B ZA 200106725 A ZA200106725 A ZA 200106725A ZA 200106725 A ZA200106725 A ZA 200106725A ZA 200106725 B ZA200106725 B ZA 200106725B
Authority
ZA
South Africa
Prior art keywords
antigen
antiparasitic
antiviral
generating
protein ompa
Prior art date
Application number
ZA200106725A
Inventor
Toufic Renno
Jean-Yves Bonnefoy
Original Assignee
Pf Medicament
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pf Medicament filed Critical Pf Medicament
Publication of ZA200106725B publication Critical patent/ZA200106725B/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/24—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
    • C07K14/26—Klebsiella (G)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/385—Haptens or antigens, bound to carriers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6068—Other bacterial proteins, e.g. OMP

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Mycology (AREA)
  • Engineering & Computer Science (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

The invention concerns the use of an enterobacterium membrane protein OmpA, in particular of Klebsiella pneumoniae, associated with an antigen or a hapten for preparing a pharmaceutical composition designed to generate or enhance a cytotoxic T response directed against a tumor cell. The invention also concerns the use of said compounds for preventing or treating infection or cancer, in particular cancers associated with a tumoral antigen such as melanoma, and pharmaceutical compositions comprising some of said compounds.
ZA200106725A 1999-02-17 2001-08-15 Use of an enterobacterium protein ompa associated with an antigen for generating an antiviral antiparasitic or antitumoral cytotoxic response. ZA200106725B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR9901917A FR2789588B1 (en) 1999-02-17 1999-02-17 USE OF AN OMPA ENTEROBACTERIA PROTEIN ASSOCIATED WITH AN ANTIGEN IN A PHARMACEUTICAL COMPOSITION FOR GENERATING OR INCREASING ANTIVIRAL, PEST CONTROL OR ANTITUMOR CYTOTOXIC RESPONSE

Publications (1)

Publication Number Publication Date
ZA200106725B true ZA200106725B (en) 2002-04-24

Family

ID=9542129

Family Applications (2)

Application Number Title Priority Date Filing Date
ZA200106725A ZA200106725B (en) 1999-02-17 2001-08-15 Use of an enterobacterium protein ompa associated with an antigen for generating an antiviral antiparasitic or antitumoral cytotoxic response.
ZA200106800A ZA200106800B (en) 1999-02-17 2001-08-17 Use of an OmpA enterobacterium protein associated with the elagigiltv peptide for treating melanomas.

Family Applications After (1)

Application Number Title Priority Date Filing Date
ZA200106800A ZA200106800B (en) 1999-02-17 2001-08-17 Use of an OmpA enterobacterium protein associated with the elagigiltv peptide for treating melanomas.

Country Status (11)

Country Link
EP (2) EP1150706A1 (en)
JP (2) JP2003506315A (en)
CN (2) CN1191090C (en)
AT (1) ATE293991T1 (en)
AU (2) AU776903B2 (en)
BR (2) BR0008307A (en)
CA (2) CA2372059A1 (en)
DE (1) DE60019725D1 (en)
FR (1) FR2789588B1 (en)
WO (2) WO2000048629A1 (en)
ZA (2) ZA200106725B (en)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2803302B1 (en) * 2000-01-04 2004-12-10 Pf Medicament PROCESS FOR THE PREPARATION OF A SOLUBLE POLYPEPTIDE BY AQUEOUS SOLVENT IN THE ABSENCE OF DETERGENT
FR2808445A1 (en) * 2000-05-04 2001-11-09 Pf Medicament OMP PROTEIN ASSOCIATED WITH A LYSATE OF AUTOLOGOUS AND / OR HETEROLOGOUS TUMOR CELLS
AU2003273472A1 (en) * 2002-07-26 2004-02-16 Pierre Fabre Medicament Method for solubilizing hydrophobic peptides and use thereof for inducing an antitumoral and/or anti-infectious ctl response
FR2842811A1 (en) * 2002-07-26 2004-01-30 Pf Medicament Solubilizing hydrophobic peptides, useful e.g. in vaccines against infectious microbes or tumors, by attachment of at least three arginine or lysine residues
FR2842812A1 (en) * 2002-07-26 2004-01-30 Pf Medicament Solubilizing hydrophobic peptides, useful e.g. in vaccines against infectious microbes or tumors, by attachment of at least three lysine residues
JP5151349B2 (en) * 2006-09-26 2013-02-27 東レ株式会社 Immune inducer and its use
EP2377883A1 (en) * 2010-04-15 2011-10-19 Universite d'Auvergne Clermont I Antagonists for the prevention or treatment of inflammatory bowel disease, and more particularly of Crohn's disease
US9314516B2 (en) * 2010-05-04 2016-04-19 Cassian Yee Conditional superagonist CTL ligands for the promotion of tumor-specific CTL responses
CN110559424B (en) * 2019-08-26 2021-08-20 君维安(武汉)生命科技有限公司 Application of outer membrane protein in preparation of malignant tumor immunotherapy medicine

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2726472B1 (en) * 1994-11-07 1997-01-31 Pf Medicament CARRIER WITH ADJUVANT EFFECT, IMMUNOGENIC COMPLEX CONTAINING THE SAME, PREPARATION METHOD THEREOF, NUCLEOTIDE SEQUENCE AND VACCINE
FR2748476B1 (en) * 1996-05-07 1998-08-14 Pf Medicament IMMUNOGENIC COMPLEX, ITS USE, ITS PREPARATION METHOD AND VACCINE CONTAINING THE SAME

Also Published As

Publication number Publication date
AU777511B2 (en) 2004-10-21
CN1191089C (en) 2005-03-02
AU2809400A (en) 2000-09-04
EP1150707B1 (en) 2005-04-27
DE60019725D1 (en) 2005-06-02
FR2789588A1 (en) 2000-08-18
WO2000048628A1 (en) 2000-08-24
AU776903B2 (en) 2004-09-23
AU2809300A (en) 2000-09-04
CA2372059A1 (en) 2000-08-24
FR2789588B1 (en) 2001-05-04
EP1150707A1 (en) 2001-11-07
JP2003506314A (en) 2003-02-18
BR0008307A (en) 2002-01-22
ZA200106800B (en) 2002-05-10
EP1150706A1 (en) 2001-11-07
WO2000048629A1 (en) 2000-08-24
CN1191090C (en) 2005-03-02
CN1341029A (en) 2002-03-20
CA2362192A1 (en) 2000-08-24
CN1344166A (en) 2002-04-10
BR0008305A (en) 2002-01-22
ATE293991T1 (en) 2005-05-15
JP2003506315A (en) 2003-02-18

Similar Documents

Publication Publication Date Title
MY140398A (en) 4-AMINO-6-PHENYL-PYRROLO[2,3-d]PYRIMIDINE DERIVATIVES
IL176007A0 (en) Antibodies specific to c35 and pharmaceutical compositions containing the same
MY136095A (en) Use of human anti-ctla-4 antibodies for treatment of cancer
MY136520A (en) Novel compounds
MY125978A (en) Admantane derivatives
EP0971717A4 (en) Cytotoxic amino sugar and related sugar derivatives of indolopyrrolocarbazoles
UA39158C2 (en) derivatives of N4-oxycarbonyl- 5'-deoxy-5-fluorocytidine and pharmaceutical preparation based thereon
DE69812159D1 (en) DERIVATIVES OF ADAMANTAN
HUP0203238A3 (en) Drugs for the treatment of malignant tumours, process for their preparation and pharmaceutical compositions containing them
NZ507350A (en) Semi-synthetic ecteinascidins and use in treatment of tumors
IL153680A0 (en) Aplidine derivatives and methods for the preparation thereof
NZ504938A (en) Tumor antigen peptide derivatives capable of binding to HLA-A24 antigen
YU68702A (en) Novel lhrh-antagonists, production and use thereof as medicament
UA85365C2 (en) Cytokine conjugation product for use in cancer therapy
ZA200106725B (en) Use of an enterobacterium protein ompa associated with an antigen for generating an antiviral antiparasitic or antitumoral cytotoxic response.
MY133112A (en) 3-amino-3-arylpropan-1-ol derivatives, and their preparation and use
IL159993A0 (en) Platinum complexes and their use in cancer treatment
HUP0100350A3 (en) Conjugates useful in the treatment of prostate cancer, pharmaceutical compositions comprising thereof, process for their preparation and their use
GB9509888D0 (en) Terpenoidic derivatives useful as antitumour agents
PL357999A1 (en) Lhrh-antagonists, production and use thereof as medicament
AU2002360350A8 (en) Peptides that home to tumor lymphatic vasculature and methods of using same
SI1305041T1 (en) Medicament for the immunotherapy of malignant tumours
AU4558201A (en) Taxane anticancer agents
PL1718651T3 (en) 7h-pyrrolopyrimidine derivatives
EP1011329A4 (en) 7-methylthiooxomethyl and 7-methylthiodioxomethyl paclitaxels